INT277117

Context Info Confidence 0.09 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.22 Pain Relevance 0.09

molecular_function (POMZP3) cellular_component (POMZP3) biological_process (POMZP3)

POMZP3 (Homo sapiens)

Pain Link Frequency Relevance Heat antagonist 11 99.92 Potency 2 77.76 headache 4 36.16 agonist 4 5.00 withdrawal 2 5.00 drug abuse 1 5.00 dopamine receptor 1 5.00 alcohol 1 5.00

Disease Link Frequency Relevance Heat Hypertension 26 84.40 Pressure Volume 2 Under Development 3 80.68 Akathisia 2 55.92 Schizophrenia 21 50.00 Psychosis 7 50.00 Headache 4 36.16 Hallucination 3 35.36 Sleep Disorders 4 33.12 Hypotension 3 26.28 Irritable Bowel Syndrome / Irritable Bowel Syndrome Super 1 18.64

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In conclusion, single dosing in healthy volunteers is sufficient for an early go/no-go decision for the Angiotensin-II receptor antagonist by providing PoM by use of a laboratory biomarker and allows establishing a dose-effect relationship predictive for short-term effects in patients.

Positive_regulation (providing) of PoM associated with antagonist

1) Confidence 0.09 Published 2007 Journal Biomarker Insights Section Body Doc Link PMC2717814 Disease Relevance 0.17 Pain Relevance 0.09

Both patient and caregiver POM ratings for aripiprazole increased during the 12-week switching phase.

Positive_regulation (increased) of POM

2) Confidence 0.04 Published 2010 Journal Ann Gen Psychiatry Section Body Doc Link PMC2949853 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.